MLL Gene Arrangement Bone Marrow Test at Chughtai Lab

MLL Gene Arrangement (Bone Marrow) at Chughtai Lab

The MLL Gene Arrangement (Bone Marrow) test, processed using the specialized National Institute of Blood Diseases (NIBD) referral pathway at Chughtai Lab, is a highly advanced molecular diagnostic assay. This test is specifically designed to detect structural alterations, translocations, and rearrangements involving the KMT2A gene, historically and commonly referred to as the Mixed-Lineage Leukemia (MLL) gene, located on chromosome 11q23. The bone marrow is the primary anatomical site of blood cell production (hematopoiesis), making it the most critical specimen source for evaluating clonal hematological malignancies. By utilizing cutting-edge molecular cytogenetic techniques such as Fluorescence In Situ Hybridization (FISH) and Polymerase Chain Reaction (PCR), clinical pathologists can identify specific genetic fusions that drive the development and progression of leukemia.

Understanding the status of the MLL gene is of paramount clinical importance in modern hematooncology. Rearrangements of this gene are key diagnostic and prognostic biomarkers in acute leukemias, including Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), and Mixed Phenotype Acute Leukemia (MPAL). The diagnostic value of this test lies in its ability to provide precise molecular classification, which is essential for risk stratification, predicting clinical outcomes, and designing targeted therapeutic regimens. For patients presenting with suspicious hematological profiles, this test offers a definitive pathway to accurate diagnosis, enabling clinicians to distinguish between standard-risk and high-risk disease variants and to monitor the therapeutic response over time.

Clinical Procedure: What to Expect

Patient Preparation

Proper patient preparation is essential to ensure safety and to obtain a high-quality bone marrow specimen for molecular analysis. Patients must follow these guidelines prior to the procedure:

• Informed Consent: The patient or a legally authorized representative must sign an informed consent form after receiving a detailed explanation of the bone marrow aspiration and biopsy procedure.
• Medication Review: Patients must inform their physician of all current medications, especially anticoagulants (such as warfarin, heparin, or enoxaparin) and antiplatelet drugs (such as aspirin or clopidogrel). These medications may need to be temporarily discontinued under medical supervision to minimize the risk of post-procedure bleeding.
• Fasting Requirements: Fasting is generally not required if the procedure is performed under local anesthesia. However, if conscious sedation or general anesthesia is planned, the patient must fast (no food or liquids) for at least 6 to 8 hours prior to the procedure.
• Pre-test Evaluations: A recent Complete Blood Count (CBC) and a coagulation profile (including PT, INR, and APTT) are typically reviewed before the procedure to assess the patient’s bleeding risk.
• Hygiene and Clothing: Patients should bathe or shower before the appointment and wear loose, comfortable clothing. They should also arrange for a family member or friend to drive them home after the procedure, especially if sedation is administered.

During the Procedure

The bone marrow collection is a sterile, invasive procedure performed by a qualified hematologist or trained clinical specialist. The process involves several key steps:

• Patient Positioning: The patient is asked to lie on their side (lateral decubitus position) or on their stomach (prone position) on an examination table to expose the posterior superior iliac spine (the back of the hip bone), which is the safest and most common site for bone marrow collection.
• Sterilization and Anesthesia: The clinical team cleanses the skin over the hip bone with an antiseptic solution and applies sterile drapes. A local anesthetic (typically lidocaine) is injected into the skin, subcutaneous tissue, and the periosteum (the sensitive outer layer of the bone) to minimize discomfort.
• Specimen Collection: Once the area is numb, the specialist inserts a specialized bone marrow aspiration needle through the bone cortex into the marrow cavity. A syringe is attached, and a small volume of liquid bone marrow (aspirate) is drawn. The patient may feel a brief, sharp pulling or suction sensation during this step. If required, a small core biopsy of the bone tissue is also obtained using a biopsy needle.
• Post-Procedure Care: The needle is removed, and firm pressure is applied to the site for several minutes to stop any bleeding. A sterile, compressive bandage is then applied. The patient is monitored for a short period to ensure there are no immediate complications.
• Specimen Handling: The collected bone marrow sample is immediately placed in appropriate transport media, labeled alongside the NIBD referral form, and dispatched to the molecular pathology department of Chughtai Lab under strict temperature-controlled conditions to preserve cellular integrity.

When is a MLL Gene Arrangement (Bone Marrow) Test Performed?

Evaluation of Acute Lymphoblastic Leukemia (ALL)

Physicians request the MLL Gene Arrangement test when evaluating patients, particularly infants and adults, suspected of having Acute Lymphoblastic Leukemia. MLL rearrangements are found in approximately 70% to 80% of infant ALL cases and are associated with an aggressive clinical course and a high risk of central nervous system involvement. Identifying this genetic alteration helps clinicians classify the leukemia subtype and initiate intensive, risk-adapted chemotherapy protocols immediately.

Diagnosis of Acute Myeloid Leukemia (AML)

This test is routinely performed during the diagnostic workup for Acute Myeloid Leukemia, especially in cases presenting with monocytic or myelomonocytic differentiation (FAB subtypes M4 and M5). The presence of specific MLL translocations, such as t(9;11), helps define distinct clinical entities within the World Health Organization (WHO) classification of hematological tumors, guiding prognostic assessment and treatment selection.

Assessment of Infant Leukemia

Leukemia presenting in infants under one year of age represents a biologically distinct disease with a high prevalence of MLL gene rearrangements. When an infant presents with symptoms such as hepatosplenomegaly, lymphadenopathy, and extreme leukocytosis, pediatric oncologists prioritize this test to confirm the molecular driver of the disease, as MLL-rearranged infant leukemias require specialized, highly intensive therapeutic strategies.

Investigation of Therapy-Related Leukemia

Patients who have previously undergone chemotherapy with topoisomerase II inhibitors (such as etoposide, teniposide, or doxorubicin) for other malignancies are at risk of developing therapy-related acute leukemia (t-AML or t-ALL). These secondary leukemias characteristically harbor MLL gene translocations. The test is performed in these patients to confirm the therapy-related nature of the disease and to guide salvage therapy or stem cell transplantation planning.

Monitoring Minimal Residual Disease (MRD)

Following the completion of induction and consolidation chemotherapy, physicians utilize highly sensitive molecular assays to detect Minimal Residual Disease. If an MLL rearrangement was identified at diagnosis, quantitative monitoring of the specific fusion transcript is performed periodically on bone marrow samples to detect early molecular relapse before clinical symptoms reappear, allowing for timely therapeutic intervention.

What Does a MLL Gene Arrangement (Bone Marrow) Test Detect?

The MLL Gene Arrangement (Bone Marrow) test is designed to detect a wide spectrum of molecular and cytogenetic abnormalities associated with the KMT2A gene. The clinical findings detectable by this assay include:

• Presence of KMT2A (MLL) gene rearrangement on chromosome 11q23.
• Absence of KMT2A (MLL) gene rearrangement, indicating a normal wild-type genetic profile.
• Specific translocation t(4;11)(q21.3;q23.3) resulting in the KMT2A-AFF1 (formerly MLL-AF4) fusion gene, highly prevalent in infant B-ALL.
• Specific translocation t(9;11)(p21.3;q23.3) resulting in the KMT2A-MLLT3 (formerly MLL-AF9) fusion gene, commonly seen in AML.
• Specific translocation t(11;19)(q23.3;p13.3) resulting in the KMT2A-MLLT1 (formerly MLL-ENL) fusion gene, observed in both AML and ALL.
• Specific translocation t(10;11)(p12.3;q23.3) resulting in the KMT2A-MLLT10 (formerly MLL-AF10) fusion gene.
• Specific translocation t(6;11)(q27;q23.3) resulting in the KMT2A-AFDN (formerly MLL-AF6) fusion gene, associated with poor prognosis.
• Specific translocation t(1;11)(q21;q23.3) resulting in the KMT2A-MLLT11 (formerly MLL-AF1q) fusion gene.
• Specific translocation t(11;19)(q23.3;p13.1) resulting in the KMT2A-ELL fusion gene.
• Specific translocation t(16;21)(q24;q22) involving MLL and RUNX1 partners in rare leukemic variants.
• MLL Partial Tandem Duplications (MLL-PTD), which are critical prognostic markers in cytogenetically normal AML.
• Numerical abnormalities of chromosome 11, such as trisomy 11, which may coexist with or mimic rearrangements.
• Deletion of the KMT2A (MLL) gene locus on one or both alleles.
• Amplification of the KMT2A (MLL) gene locus, indicating genomic instability.
• Complex multi-way translocations involving chromosome 11q23 and multiple partner chromosomes.
• Subclonal MLL rearrangements, reflecting clonal evolution and disease progression.
• Rare or novel fusion partner genes (over 100 distinct partner genes have been characterized for KMT2A).
• Co-existing molecular mutations (e.g., FLT3-ITD, NPM1, or TP53 mutations) that modify the prognostic impact of the MLL rearrangement.
• Clearance of MLL fusion transcripts post-therapy, indicating complete molecular remission.
• Re-emergence or increasing levels of MLL fusion transcripts, indicating impending clinical relapse.
• Lineage-plasticity markers associated with MLL-rearranged leukemias, which can present as mixed-phenotype acute leukemia.

Turnaround Time and Report Access at Chughtai Lab

Due to the highly specialized and complex nature of molecular cytogenetics and polymerase chain reaction (PCR) technologies, the MLL Gene Arrangement (Bone Marrow) test requires meticulous laboratory processing and expert interpretation. At Chughtai Lab, the standard turnaround time for this molecular assay is typically 7 to 10 working days. This timeline ensures that the bone marrow sample undergoes rigorous quality control, DNA/RNA extraction, hybridization or amplification, and detailed analysis by a team of qualified molecular pathologists and hematopathologists.

Once the analysis is complete, the final report is reviewed and signed off by senior consultants. Chughtai Lab provides multiple convenient methods for patients and referring physicians to access reports. Reports can be downloaded directly from the Chughtai Lab official website portal using the patient’s lab number and password. Additionally, patients can access their diagnostic reports through the Chughtai Lab mobile application, available on iOS and Android platforms. Hard copies of the reports can also be collected from any of the numerous Chughtai Lab collection centers located across Pakistan.

MLL Gene Arrangement Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
KMT2A (MLL) Gene Status	Intact gene locus on chromosome 11q23 (No rearrangement)	Rearrangement, translocation, or disruption of the KMT2A gene locus detected
t(4;11) Translocation	Negative (No KMT2A-AFF1 fusion)	Positive (Presence of KMT2A-AFF1 fusion; associated with high-risk B-ALL)
t(9;11) Translocation	Negative (No KMT2A-MLLT3 fusion)	Positive (Presence of KMT2A-MLLT3 fusion; common in AML with intermediate prognosis)
t(11;19) Translocation	Negative (No KMT2A-MLLT1 fusion)	Positive (Presence of KMT2A-MLLT1 fusion; seen in infant and pediatric leukemias)
MLL Partial Tandem Duplication (MLL-PTD)	Absent	Present (Associated with poor prognosis in cytogenetically normal AML)
Gene Copy Number	Two intact copies of the KMT2A gene per diploid cell	Deletion (one copy) or Amplification/Duplication (three or more copies)
Bone Marrow Cellularity & Blast Count	Normal age-appropriate cellularity; blasts < 5%	Hypercellular marrow with > 20% blasts harboring MLL rearrangements
Minimal Residual Disease (MRD) Level	Undetectable MLL fusion transcripts	Detectable MLL fusion transcripts post-treatment (indicates persistent disease or early relapse)

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for MLL Gene Arrangement Testing?

• Collaborative Expertise: Chughtai Lab utilizes specialized diagnostic pathways, including the NIBD referral system, ensuring that complex bone marrow reports are interpreted by the country’s leading hematopathologists.
• Advanced Molecular Diagnostics: Our molecular pathology division is equipped with state-of-the-art FISH and PCR platforms, providing high sensitivity and specificity for genetic translocation detection.
• ISO 15189 Certification: Chughtai Lab operates under strict international quality standards, ensuring accuracy, reliability, and reproducibility of all molecular test results.
• Expert Pathologist Review: Every molecular oncology report is reviewed and signed off by highly qualified, board-certified molecular pathologists and clinical hematologists.
• Nationwide Network: With hundreds of collection centers across Pakistan, Chughtai Lab offers unparalleled accessibility for specimen submission and report collection.
• Digital Report Access: Patients and physicians can easily view, download, and share reports online via the Chughtai Lab web portal and mobile application.
• Strict Quality Control: The laboratory participates in rigorous external quality assurance programs to maintain the highest standards of diagnostic precision.
• Patient-Centric Care: We provide a supportive and professional environment, ensuring that patients receive compassionate care throughout their diagnostic journey.